Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Scandinavian Journal of Rheumatology|October 14, 2016
Intra-articular onabotulinumtoxinA in osteoarthritis knee pain: effect on human mechanistic pain biomarkers and clinical painL Arendt-Nielsen, G-L Jiang, R DeGryse, et al.Expert Opinion on Investigational Drugs|July 5, 2005
Dichloroacetate and cerebral ischaemia therapeuticsP J Marangos, C C Turkel, Z E Dziewanowska, et al.Neurology|January 29, 2011
Rates, predictors, and consequences of remission from chronic migraine to episodic migraineA Manack, D C Buse, D Serrano, et al.Journal of Clinical Pharmacology|March 28, 2001
Dichloroacetate: population pharmacokinetics with a pharmacodynamic sequential link modelP J Williams, J R Lane, C C Turkel, et al.Cephalalgia : an International Journal of Headache|July 21, 2009
Global prevalence of chronic migraine: a systematic reviewJ L Natoli, A Manack, B Dean, et al.European Journal of Neurology|March 18, 2014
Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraineH-C Diener, D W Dodick, C C Turkel, et al.Acta Neurologica Scandinavica|October 11, 2013
OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical programS K Aurora, D W Dodick, H-C Diener, et al.Cephalalgia : an International Journal of Headache|July 22, 2010
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialH C Diener, D W Dodick, S K Aurora, et al.Cephalalgia : an International Journal of Headache|July 22, 2010
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialS K Aurora, D W Dodick, C C Turkel, et al.Neurology|November 23, 2000
MR spectroscopy study of dichloroacetate treatment after ischemic strokeG D Graham, P B Barker, W M Brooks, et al.Pageof 2